Silexion Therapeutics Corp
SLXNNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · E9 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$11.6M | −$12.6M | −$4.7M |
| Net income | −$11.9M | −$16.5M | −$5.1M |
| Total assets | $7.2M | $2.9M | $5.3M |
| Total liabilities | $4.6M | $6.9M | $2.3M |
| Equity | $2.6M | −$4.0M | −$15.5M |
| EPS (diluted) | $8.96 | $394.94 | $44.23 |
| Shares out. | 3.13B | 8.41B | 97.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −457.6%
- Return on assets
- −165.1%
- Return on capital (ROCE)
- −261.0%
- Liabilities / assets
- 63.9%
- Debt / equity
- 1.77×
- Book value / share
- $0.00
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -31.64distress
- Accruals / assets
- −15.1%clean
- Piotroski F-Score
- 5/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Moringa Sponsor, LpActivist (13D)May 29, 2026
- Lind Global Fund Iii LpPassive (13G)May 15, 2026
- Intracoastal Capital, LlcPassive (13G)Feb 13, 2026
- Orca Capital AgPassive (13G)Sep 15, 2025
- Lincoln Alternative Strategies LlcPassive (13G)Sep 15, 2025
- Wildcat Capital Management, LlcActivist (13D)Jun 26, 2025
- Goldman Sachs Group IncPassive (13G)May 13, 2025
- Cvi Investments, Inc.Passive (13G)May 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Shirvan MitchellOfficer — CSO and CDO | Mar 26, 2026 | Sell | 22,818 | $1.36 |
| Noy ShlomoDirector | Feb 20, 2026 | Grant | 9,091 | $0.00 |
| Alon RuthDirector | Feb 20, 2026 | Grant | 9,091 | $0.00 |
| Shirvan MitchellOfficer — CSO and CDO | Feb 20, 2026 | Grant | 49,726 | $0.00 |
| Horenshtein Hadar MiritOfficer — CFO and Secretary | Feb 20, 2026 | Grant | 49,726 | $0.00 |
| Hadar IlanOfficer — Chairman and CEO | Feb 20, 2026 | Grant | 64,350 | $0.00 |
| Abramov Dror YosefDirector | Feb 20, 2026 | Grant | 9,091 | $0.00 |
| Peled AmnonDirector | Feb 20, 2026 | Grant | 7,576 | $0.00 |
| Lushi AvnerDirector | Feb 20, 2026 | Grant | 9,091 | $0.00 |
| Levin IlanDirector | Aug 7, 2025 | J | 5,550 | $0.00 |
| Abramov Dror YosefDirector | Feb 9, 2025 | Grant | 794 | $0.00 |
| Alon RuthDirector | Feb 9, 2025 | Grant | 794 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 159,027 | 1.0 | +380.1% |
| Apr 30, 2026 | 33,126 | 1.0 | -28.7% |
| Apr 15, 2026 | 46,472 | 1.0 | -6.9% |
| Mar 31, 2026 | 49,913 | 1.1 | +5.2% |
| Mar 13, 2026 | 47,438 | 1.7 | +4.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Modified shareholder rights · Amended charter or bylaws · Other material eventMay 29, 2026
- Other material eventMay 26, 2026
- Results of operationsMay 18, 2026
- Entered a material agreement · Unregistered equity saleMay 15, 2026
- Regulation FD disclosureMay 14, 2026
- Regulation FD disclosureMay 13, 2026
- Amended charter or bylaws · Shareholder voteMay 5, 2026
- Regulation FD disclosureApr 28, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.